To discover effective combination strategies for FAK inhibition, we performed a chemotherapeutic drug screen to test the overall cell-killing effects of conventional chemotherapies with or without supplementation of IN10018 in 2 ovarian cancer cell lines, A2780 and SK-OV-3 (Fig. 1I-K). This evidence concerns the gene PTK2 and ovarian cancer.